Business Context and Reporting Period
Revolution Medicines, Inc. filed a Form 8-K on August 26, 2026, reporting a significant regulatory milestone. The company is a biopharmaceutical firm focused on developing targeted therapies.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed is the wholesale acquisition cost of the newly approved drug, RASONQUE, which is $39,800 for a 30-day supply.
Material Changes
The primary material event is the U.S. Food and Drug Administration (FDA) approval of RASONQUE (daraxonrasib) on August 26, 2026. The approval covers the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This approval is based on data from the RASolute 302 Phase 3 clinical trial.
Guidance, Outlook, and Management Commentary
Management confirmed that once-daily oral RASONQUE tablets are immediately available in the United States for physicians to prescribe to eligible patients. The filing does not provide specific revenue guidance, future outlook projections, or detailed risk factors beyond the standard regulatory context.
Investor Verification Checklist
- Verify the specific patient eligibility criteria for RASONQUE as defined in the FDA label.
- Confirm the commercial launch timeline and distribution strategy for RASONQUE.
- Review the full RASolute 302 clinical trial data to understand the efficacy and safety profile supporting the approval.
- Assess the competitive landscape for metastatic pancreatic adenocarcinoma treatments to gauge market share potential.
- Monitor upcoming financial reports for the impact of RASONQUE sales on revenue and cash flow.